|Bid||44.88 x 800|
|Ask||45.00 x 900|
|Day's Range||44.26 - 45.35|
|52 Week Range||23.61 - 56.67|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.00|
Novocure (NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information. In 2018, Novocure made a commitment to put into words its vision, mission and values as part of its corporate objective of investing in its people and culture.
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$4.4b. However, an important fact which most ignore is: how financially healthy is the business...
Despite last month's pullback, shares of this medical device company that's aiming to revolutionize cancer treatment are up 126% over the last year.
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.
Novocure (NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2019, at 8 a.m. EDT on Thursday, May 2, 2019. The webcast and earnings slides presented during the webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the call.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Novocure (NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma.
A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment
Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president of clinical development, will assume responsibilities for preclinical and clinical development and regulatory affairs effective immediately, and Ely Benaim will join the company as chief medical officer effective April 1, assuming responsibilities for clinical operations, medical affairs and safety. The stock, which is still inactive in premarket trade has soared 67.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 24.6% and the S&P 500 has climbed 16.9%.
Novocure (NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family. “While this was a difficult decision, it is the right one for my family,” stated Dr. Kirson.
Novocure announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019, in New York City.
Analyzing NovoCure Limited's (NASDAQ:NVCR) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 100,000 shares of NVCR on 03/01/2019 at an average price of $55.57 a share.
Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018
Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 200,000 shares of NVCR on 01/17/2019 at an average price of $45.16 a share.
Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]
Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.
Novocure will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts.